Welcome to our dedicated page for Portage Biotech SEC filings (Ticker: PRTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PRTG SEC filings page on Stock Titan aggregates regulatory documents originally filed as Portage Biotech Inc. and, following its name change, as AlphaTON Capital Corp. The company is a foreign private issuer formed under the laws of the British Virgin Islands and files annual reports on Form 20-F and current reports on Form 6-K. These filings trace the evolution from a clinical-stage immuno-oncology company to an issuer with two primary business lines: a legacy oncology R&D portfolio and a digital asset treasury strategy focused on The Open Network (TON) token.
For investors analyzing the legacy PRTG listing, Form 6-K reports and accompanying exhibits provide details on clinical and preclinical programs, including PORT-6 and PORT-7, as well as financial statements, operating expenses, and research and development trends. Other filings describe capital-raising activities such as private placements of ordinary shares and pre-funded warrants, at-the-market offering agreements under an effective Form F-3 shelf registration statement, and related legal opinions and placement agent agreements.
More recent 6-K filings under the AlphaTON Capital Corp name outline the company’s TON-focused strategy, including a private placement offering funded with cash and cryptocurrency, a loan agreement with a digital asset lender, and a treasury management agreement for TON holdings. These documents explain how net proceeds are expected to be allocated between cryptocurrency acquisitions and the legacy immune-oncology business, and they describe associated registration rights and lock-up arrangements.
On Stock Titan, SEC filings linked to the historical PRTG symbol are updated in near real time from EDGAR and can be paired with AI-powered summaries that highlight key terms, business descriptions, financing structures, and risk disclosures. This helps readers quickly understand how the company’s strategy, capital structure, and even its name and ticker have changed, while still allowing access to the full original filings for detailed review.
AlphaTON Capital Corp established an at-the-market share offering program allowing it to sell up to
The company plans to use any net proceeds to fund capital spending for development, training and operation of its Cocoon AI platform, including servers, GPUs and related infrastructure, to pursue complementary acquisitions or investments, and for working capital and other general corporate purposes.
AlphaTON Capital Corp is launching an at-the-market equity program to sell up to $400,000,000 of ordinary shares through H.C. Wainwright as sales agent or principal. Shares may be sold from time to time on Nasdaq under the symbol ATON or through other permitted methods at prevailing market prices.
The company plans to use net proceeds mainly to fund capital expenditures for Cocoon AI, including servers, GPUs and related infrastructure, and to pursue strategic acquisitions or investments aligned with the Telegram and TON ecosystem, with any remainder for working capital and general corporate purposes.
As context, AlphaTON reports 23,434,588 ordinary shares outstanding as of February 13, 2026, so issuing a large portion of the program would significantly increase the share count and dilute existing holders. Wainwright will receive up to a 3.0% sales commission on gross proceeds.
AlphaTON Capital Corp reported changes to its board of directors. On February 5, 2026, Steven Mintz informed the company that he would resign from the board, effective February 6, 2026.
On February 6, 2026, F. Daniel Siciliano joined the board following a unanimous vote in favor by the existing directors, providing continuity in board governance following the resignation.
AlphaTON Capital Corp received an amended ownership report showing that Orca Capital, a Germany-based investor, beneficially owns 640,000 Ordinary Shares, equal to 4.5% of the class. Orca has sole power to vote and dispose of all these shares.
The percentage is calculated using 14,314,588 Ordinary Shares outstanding, reflecting AlphaTON’s registered offering described in a prospectus filed on January 15, 2026. Orca filed on a passive basis, certifying the shares were not acquired to change or influence control of the company.
AlphaTON Capital Corp reported that it has raised net
The company closed a
AlphaTON exited SEC baby-shelf limits and obtained effectiveness for a
AlphaTON Capital Corp filed an amended Form 6-K to add unaudited condensed interim financial statements and XBRL data for the three and six months ended September 30, 2025. The company has pivoted from a legacy immuno-oncology focus to a technology and digital-asset strategy built around the Telegram ecosystem and TON blockchain, including staking, DeFi activities and Telegram-based applications.
For the six months ended September 30, 2025, AlphaTON reported a net loss of about $11.1 million, with basic and diluted loss per share of $5.13. As of September 30, 2025, cash and cash equivalents were $0.2 million against current liabilities of $21.5 million, while total assets were $30.6 million, including stablecoins of $3.1 million, digital assets of $1.8 million, and digital asset and stablecoin receivables of $23.9 million.
In September 2025 the company completed a private placement of ordinary shares and pre-funded warrants with aggregate consideration of approximately $36.2 million in cash, digital assets and stablecoins, and recognized a put right liability of $17.9 million related to contingent repurchase and treasury arrangements. The financial statements include a going concern note stating that recurring losses, limited cash and reliance on external financing raise substantial doubt about the company’s ability to continue as a going concern within one year of the statements’ issuance date.
AlphaTON Capital Corp outlines key terms of a planned financing and related agreements to support a TON digital asset treasury strategy for the Telegram ecosystem. Under a treasury management agreement, the company will appoint DWF MaaS Limited to manage an initial
The company expects gross proceeds of about
Alphaton Capital Corp. entered into an at-the-market offering agreement with Chardan Capital Markets, LLC, allowing it to sell ordinary shares from time to time with an aggregate offering price of up to $2,841,450 under its effective Form F-3 shelf registration.
Chardan will act as sales agent and/or principal and receive a 3.0% cash commission on the gross sales price of any shares sold, plus expense reimbursement. The program will end when all $2,841,450 of shares are sold under the prospectus supplement or the agreement is otherwise terminated.
Portage Biotech Inc. files a prospectus supplement describing an offering of securities and related risks, governance and tax considerations. The supplement discloses the potential issuance of approximately 3,746,443 ordinary shares and 2,921,808 ordinary shares upon settlement of pre-funded warrants from a private placement, plus multiple tranches of shares reserved for executives, employees, contractors, service providers and equity incentives (including specific amounts such as 478,851, 17,452, 244,221, 191,980, and 47,828 ordinary shares under various agreements).
The supplement highlights material risks: exposure to a recently developed digital asset (TON) with potential volatility and custody/insurance shortcomings; debt-related risks including default, acceleration and loss of collateral; limited liquidity and trading risks (including penny-stock designation); and data-protection obligations and penalties under the British Virgin Islands data protection regime. The document also lists incorporated SEC reports and the Form 8-A description of ordinary shares as sources of further detail.
Portage Biotech Inc. (PRTG) filed a Form 6‑K disclosing a set of material agreements and company documents made available as exhibits. The filing lists an At‑The‑Market Offering Agreement with Chardan Capital Market, LLC (
These exhibits indicate preparatory financing activity (equity and cryptocurrency securities), new counterparty credit arrangements, and expanded external contractor relationships. The combination of an ATM facility, registration rights and debt with a crypto custodian suggests the company is arranging capital and operational partnerships to support near‑term funding and execution; however, the filing provides exhibit descriptions only and does not disclose monetary sizes, pricing, or full contractual terms within this document.